Persistent HPV infection is the principal cause of cervical cancer. HPV-based screening is effective but has limited ...

BD Onclarity™ HPV Assay is the only FDA-approved HPV assay to individually identify and report genotypes beyond 16, 18 and 45 FRANKLIN LAKES, N.J., July 22, 2020 /PRNewswire/ -- BD (Becton, Dickinson ...

MIAMI, FLORIDA, USA, June 20, 2024 /EINPresswire.com/ -- Mel-Mont Medical, Inc., an innovative leader in precision HPV mRNA extended genotyping and sample collection ...

ATHENA study shows the cobas HPV Test advances the standard of care by providing valuable information on the risks associated with the genotypes which cause 70 percent of cervical cancer Results from ...

- Presented a roadmap to enhance screening reliability at the world's leading multidisciplinary HPV congress held in Portugal from March 16-19 - Demonstrated how self-collected samples for HPV testing ...

FRANKLIN LAKES, N.J., Nov. 12, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has submitted a pre-market ...

The American Society for Colposcopy and Cervical Pathology (ASCCP) has issued new guidelines reflecting the importance of extended genotyping in HPV testing to support an enhanced standard of patient ...

The U.S. Human Papilloma Virus (HPV) testing market is poised for significant growth, projected to reach $1.01 billion by ...

Abbott Laboratories is adding HPV screening to its "Alinity m" family of diagnostic assays following U.S. Food & Drug Administration approval. Abbott said in a press release that the FDA approved its ...